0001434265--12-312022Q2falseGenmab A/S6-K2022-06-3000014342652022-01-012022-06-300001434265gmab:PropertiesMember2022-06-300001434265gmab:IfrsEquipmentMember2022-06-300001434265gmab:PropertiesMember2021-06-300001434265gmab:IfrsEquipmentMember2021-06-300001434265gmab:TepezzaMembergmab:RoyaltiesRevenueMember2022-01-012022-06-300001434265gmab:OtherRoyaltyProductMembergmab:RoyaltiesRevenueMember2022-01-012022-06-300001434265gmab:KesimptaMembergmab:RoyaltiesRevenueMember2022-01-012022-06-300001434265gmab:DarzalexMembergmab:RoyaltiesRevenueMember2022-01-012022-06-300001434265gmab:RoyaltiesRevenueMember2022-01-012022-06-300001434265gmab:ReimbursementIncomeMember2022-01-012022-06-300001434265gmab:OtherCollaborationPartnersMember2022-01-012022-06-300001434265gmab:MilestonePaymentsRevenueMember2022-01-012022-06-300001434265gmab:CollaborationRevenueMember2022-01-012022-06-300001434265gmab:AgreementsWithSeagenMember2022-01-012022-06-300001434265gmab:AgreementsWithRocheMember2022-01-012022-06-300001434265gmab:AgreementsWithNovartisMember2022-01-012022-06-300001434265gmab:AgreementsWithJanssenMember2022-01-012022-06-300001434265gmab:AgreementsWithBointechMember2022-01-012022-06-300001434265gmab:TepezzaMembergmab:RoyaltiesRevenueMember2021-01-012021-06-300001434265gmab:OtherRoyaltyProductMembergmab:RoyaltiesRevenueMember2021-01-012021-06-300001434265gmab:KesimptaMembergmab:RoyaltiesRevenueMember2021-01-012021-06-300001434265gmab:DarzalexMembergmab:RoyaltiesRevenueMember2021-01-012021-06-300001434265gmab:RoyaltiesRevenueMember2021-01-012021-06-300001434265gmab:ReimbursementIncomeMember2021-01-012021-06-300001434265gmab:MilestonePaymentsRevenueMember2021-01-012021-06-300001434265gmab:AgreementsWithSeagenMember2021-01-012021-06-300001434265gmab:AgreementsWithRocheMember2021-01-012021-06-300001434265gmab:AgreementsWithNovartisMember2021-01-012021-06-300001434265gmab:AgreementsWithJanssenMember2021-01-012021-06-300001434265gmab:AgreementsWithBointechMember2021-01-012021-06-300001434265gmab:AgreementsWithAbbvieMember2021-01-012021-06-300001434265gmab:CurevacCollaborationMember2022-06-300001434265gmab:BoltBiotherapeuticsIncMember2022-06-300001434265gmab:CurevacCollaborationMember2021-12-310001434265gmab:BoltBiotherapeuticsIncMember2021-12-310001434265ifrs-full:SharePremiumMember2022-01-012022-06-300001434265ifrs-full:SharePremiumMember2021-01-012021-06-300001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-06-300001434265gmab:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-06-300001434265gmab:MarketableSecuritiesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2022-06-300001434265gmab:OtherInvestmentMemberifrs-full:AtFairValueMember2022-06-300001434265gmab:MarketableSecuritiesMemberifrs-full:AtFairValueMember2022-06-300001434265gmab:OtherInvestmentMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-12-310001434265gmab:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:AtFairValueMember2021-12-310001434265gmab:OtherInvestmentMemberifrs-full:AtFairValueMember2021-12-310001434265gmab:MarketableSecuritiesMemberifrs-full:AtFairValueMember2021-12-310001434265ifrs-full:SharePremiumMember2022-06-300001434265ifrs-full:RetainedEarningsMember2022-06-300001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001434265ifrs-full:IssuedCapitalMember2022-06-300001434265ifrs-full:SharePremiumMember2021-12-310001434265ifrs-full:RetainedEarningsMember2021-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001434265ifrs-full:IssuedCapitalMember2021-12-310001434265ifrs-full:SharePremiumMember2021-06-300001434265ifrs-full:RetainedEarningsMember2021-06-300001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001434265ifrs-full:IssuedCapitalMember2021-06-300001434265ifrs-full:SharePremiumMember2020-12-310001434265ifrs-full:RetainedEarningsMember2020-12-310001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001434265ifrs-full:IssuedCapitalMember2020-12-310001434265gmab:PropertiesMember2022-01-012022-06-300001434265gmab:IfrsEquipmentMember2022-01-012022-06-300001434265gmab:PropertiesMember2021-01-012021-06-300001434265gmab:IfrsEquipmentMember2021-01-012021-06-300001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-06-300001434265ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-3000014342652021-06-3000014342652022-04-012022-06-3000014342652021-04-012021-06-300001434265gmab:IfrsRestrictedStockUnitsRSUsMember2022-01-012022-06-300001434265gmab:IfrsRestrictedStockUnitsRSUsMember2021-01-012021-06-300001434265gmab:RestrictedStockUnitsRSUsMember2022-01-012022-06-300001434265gmab:StockRepurchaseAuthorization2021Member2022-01-012022-06-300001434265gmab:StockRepurchaseAuthorization2019Member2022-01-012022-06-300001434265gmab:StockRepurchaseAuthorization2016Member2022-01-012022-06-300001434265gmab:DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember2022-03-292022-03-2900014342652020-12-310001434265ifrs-full:CurrencyRiskMembercurrency:USD2022-01-012022-06-300001434265ifrs-full:CurrencyRiskMembercurrency:GBP2022-01-012022-06-300001434265ifrs-full:CurrencyRiskMembercurrency:EUR2022-01-012022-06-300001434265ifrs-full:CurrencyRiskMembercurrency:DKK2022-01-012022-06-300001434265ifrs-full:CurrencyRiskMember2022-01-012022-06-300001434265ifrs-full:CurrencyRiskMembercurrency:USD2021-01-012021-12-310001434265ifrs-full:CurrencyRiskMembercurrency:GBP2021-01-012021-12-310001434265ifrs-full:CurrencyRiskMembercurrency:EUR2021-01-012021-12-310001434265ifrs-full:CurrencyRiskMembercurrency:DKK2021-01-012021-12-310001434265ifrs-full:CurrencyRiskMember2021-01-012021-12-310001434265gmab:TripleaRatingMemberifrs-full:CreditRiskMember2022-06-300001434265gmab:TripleaRatingMemberifrs-full:CreditRiskMember2021-12-310001434265gmab:WarrantsMember2022-01-012022-06-300001434265gmab:WarrantsMember2021-01-012021-06-300001434265gmab:StockRepurchaseAuthorization2021Member2022-06-300001434265gmab:StockRepurchaseAuthorization2019Member2022-06-300001434265gmab:StockRepurchaseAuthorization2016Member2022-06-300001434265ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2022-03-292022-03-290001434265ifrs-full:RetainedEarningsMember2022-01-012022-06-300001434265ifrs-full:RetainedEarningsMember2021-01-012021-06-3000014342652022-06-300001434265gmab:OfficeAndLaboratorySpaceMembercountry:DK2022-06-300001434265gmab:MijkeZachariasseMartinSchultzAndTakahiroHamataniMember2022-03-292022-03-290001434265gmab:ElizabethOfarrellMember2022-03-292022-03-2900014342652021-12-3100014342652021-01-012021-06-30iso4217:DKKgmab:itemgmab:directorxbrli:sharesxbrli:pureiso4217:DKKxbrli:sharesgmab:EquityInstruments

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2022

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes  No 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes  No 

Exhibit 99.1 to this report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statement on Form S-8 (File No. 333-232693) and in the outstanding prospectus contained in such registration statement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENMAB A/S

BY:

/s/ Anthony Pagano

Name: Anthony Pagano

Title: Executive Vice President & Chief Financial Officer

DATE: August 10, 2022

EXHIBIT INDEX

A

Exhibit

Description of Exhibit

99.1

Interim Report Dated August 10, 2022

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

Interim Report for the 6 months ended June 30, 2011

Exhibit 99.1

Graphic

Genmab Announces Financial Results for the First Half of 2022

August 10, 2022 Copenhagen, Denmark;

Interim Report for the First Six Months Ended June 30, 2022

Highlights

Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL)
Genmab announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for epcoritamab for the treatment of patients with relapsed/refractory LBCL, in the second half of 2022
DARZALEX® net sales as reported by Johnson & Johnson increased 37% compared to the first six months of 2021 to USD 3,842 million, resulting in royalty revenue to Genmab of DKK 4,024 million
Genmab announced the resolution of its arbitration with Janssen Biotech, Inc. (Janssen) under its daratumumab license agreement and subsequently commenced a new arbitration under the daratumumab license agreement with Janssen
Genmab improves its 2022 financial guidance

“Genmab’s innovation was on display during the second quarter of 2022 with data presentations at multiple prestigious conferences and the publication by Genmab, and our partner, AbbVie, of topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory LBCL. Based on this data, we intend to submit a BLA to the U.S. FDA for epcoritamab in the second half of this year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Half of 2022

Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022 compared to USD 2,798 million in the first six months of 2021, an increase of USD 1,044 million, or 37%.
Royalty revenue was DKK 4,727 million in the first six months of 2022 compared to DKK 2,595 million in the first six months of 2021, an increase of DKK 2,132 million, or 82%. The increase in royalties was driven by higher net sales of DARZALEX, TEPEZZA® and Kesimpta® and higher average exchange rate between the USD and DKK.
Revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021. The increase of DKK 1,728 million, or 49%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our collaborations with Janssen, Roche and Novartis Pharma AG (Novartis), respectively, partly offset by milestones achieved under our collaborations with Janssen and AbbVie in the first six months of 2021.
Operating expenses were DKK 3,520 million in the first six months of 2022 compared to DKK 2,234 million in the first six months of 2021. The increase of DKK 1,286 million, or 58%, was driven by the continued advancement of epcoritamab and multiple pipeline projects, an increase in new employees to support Tivdak® post launch and expansion of our product pipeline, and the continued development of Genmab’s commercialization and broader organizational capabilities and infrastructure.
Operating profit was DKK 1,761 million in the first six months of 2022 compared to DKK 1,319 million in the first six months of 2021.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 1/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Genmab Announces Financial Results for the First Half of 2022

Outlook

As announced in Company Announcement No. 40, Genmab is raising its 2022 financial guidance published on May 11, 2022, driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the foreign exchange impact of the strong US Dollar.

Revised

Previous

(DKK million)

    

Guidance

    

Guidance

    

Revenue

 

12,000 - 13,000

 

11,000 - 12,000

 

Operating expenses

 

(7,600) - (8,200)

 

(7,200) - (7,800)

 

Operating profit

 

3,800 - 5,400

 

3,200 - 4,800

 

Conference Call

Genmab will hold a conference call in English to discuss the results for the first half of 2022 today, Wednesday, August 10, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call dial

+1 631 913 1422 (U.S. participants) or +44 3333000804 (international participants) and provide conference code 29756170. A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.

Contact:

Marisol Peron, Senior Vice President, Communications and Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 2/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

CONTENTS

MANAGEMENT’S REVIEW

CONSOLIDATED KEY FIGURES

4

OUTLOOK

5

KEY 2022 PRIORITIES

6

PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST HALF OF 2022

6

SIGNIFICANT RISKS AND UNCERTAINTIES

14

FINANCIAL REVIEW

15

FINANCIAL STATEMENTS

STATEMENTS OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2022

21

STATEMENTS OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2022

22

BALANCE SHEETS AS OF JUNE 30, 2022

23

STATEMENTS OF CASH FLOWS FOR THE FIRST HALF OF 2022

24

STATEMENTS OF CHANGES IN EQUITY FOR THE FIRST HALF OF 2022

25

NOTES TO THE FINANCIAL STATEMENTS

26

ABOUT GENMAB

34

DIRECTORS’ AND MANAGEMENT’S STATEMENT ON THE INTERIM REPORT

35

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 3/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

CONSOLIDATED KEY FIGURES

  

2nd Quarter of

  

2nd Quarter of

6 Months Ended

  

6 Months Ended

Full Year

2022

2021

June 30, 2022

June 30, 2021

2021

(DKK million)

Income Statement

 

  

  

 

  

Revenue

 

3,162

1,972

5,281

3,553

8,482

Research and development expenses

 

(1,282)

(921)

(2,435)

(1,769)

(4,181)

Selling, general and administrative expenses

 

(633)

(264)

(1,085)

(465)

(1,283)

Operating expenses

 

(1,915)

(1,185)

(3,520)

(2,234)

(5,464)

Operating profit

 

1,247

787

1,761

1,319

3,018

Net financial items

 

1,242

(365)

1,340

527

965

Net profit

 

1,891

306

2,356

1,402

3,008

Balance Sheet

 

Marketable securities

 

11,799

8,398

11,799

8,398

10,381

Cash and cash equivalents

9,816

9,477

9,816

9,477

8,957

Total non-current assets

 

1,985

2,179

1,985

2,179

1,891

Total assets

 

27,476

22,483

27,476

22,483

24,627

Shareholders' equity

 

24,482

20,252

24,482

20,252

22,196

Share capital

 

66

66

66

66

66

Cash Flow Statement

 

Cash flow from operating activities

 

959

355

1,546

1,540

2,228

Cash flow from investing activities

 

(576)

1,545

(1,243)

966

(961)

Cash flow from financing activities

 

(214)

(240)

(278)

(460)

(420)

Investment in tangible assets

 

(68)

(79)

(125)

(107)

(252)

Financial Ratios and Other Information

 

 

Basic net profit per share

 

28.87

4.68

35.97

 

21.44

46.00

Diluted net profit per share

 

28.66

4.64

35.71

 

21.25

45.54

Period-end share market price

 

2,297

2,566

2,297

 

2,566

2,630

Price / book value

 

6.19

8.36

6.19

 

8.36

7.82

Shareholders' equity per share

 

370.94

306.85

370.94

 

306.85

336.30

Equity ratio

 

89

%

90

%

89

%

90

%

90

%

Shares outstanding

65,753,443

65,620,740

65,753,443

65,620,740

65,718,456

Average number of employees (FTE*)

 

1,406

969

1,345

 

906

1,022

Number of employees (FTE) at the end of the period

 

1,445

1,029

1,445

 

1,029

1,212

* Full-time equivalent or team members

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 4/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

OUTLOOK

Revised

Previous

(DKK million)

    

Guidance

    

Guidance

    

Revenue

 

12,000 - 13,000

 

11,000 - 12,000

 

Operating expenses

 

(7,600) - (8,200)

 

(7,200) - (7,800)

 

Operating profit

 

3,800 - 5,400

 

3,200 - 4,800

 

Genmab is raising its 2022 financial guidance published on May 11, 2022, driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the foreign exchange impact of the strong US Dollar.

Revenue

Genmab expects its 2022 revenue to be in the range of DKK 12,000 – 13,000 million, an increase to the previous guidance of DKK 11,000 – 12,000 million, driven primarily by the expected continued strong growth of DARZALEX net sales as well as the positive impact of the strong US Dollar. Genmab’s projected revenue for 2022 primarily consists of DARZALEX royalties of DKK 8,800 – 9,300 million compared to the previous guidance of DKK 8,000 – 8,500 million. Such royalties are based on Genmab’s revised estimate of DARZALEX 2022 net sales of USD 7.8 – 8.2 billion compared to the previous guidance of USD 7.5 – 8.0 billion. DARZALEX royalties are partly offset by Genmab’s share of Janssen’s royalty payments to Halozyme in connection with subcutaneous (SC) net sales. The remainder of Genmab’s revenue primarily consists of royalties from TEPEZZA, Kesimpta and RYBREVANT®, reimbursement revenue, milestones for epcoritamab, teclistamab and other milestones as well as collaboration revenue with Seagen for Tivdak.

Operating Expenses

Genmab anticipates its 2022 operating expenses to be in the range of DKK 7,600 – 8,200 million, an increase to the previous guidance of DKK 7,200 – 7,800 million, driven by increased investment related to pipeline progression and epcoritamab launch readiness activities as well as the negative impact of the strong US Dollar. Operating expenses continue to be driven by the advancement of Genmab’s clinical programs, continued investment in research and development, as well as building Genmab’s commercial organization and broader organizational infrastructure.

Operating Profit

Genmab now expects its 2022 operating profit to be in the range of DKK 3,800 – 5,400 million, an increase to the previous guidance of DKK 3,200 – 4,800 million, driven primarily by the items described above.

Outlook: Risks and Assumptions

In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab’s collaboration agreements; the timing and variation of development activities (including activities carried out by Genmab’s collaboration partners) and related income and costs; DARZALEX, Kesimpta, TEPEZZA and RYBREVANT net sales and royalties paid to Genmab; and currency exchange rates (the 2022 guidance assumes a USD / DKK exchange rate of 6.8 compared to 6.4 in the previous guidance). The financial guidance assumes that no significant new agreements are entered into during the remainder of 2022 that could materially affect the results. Refer to the section “Significant Risks and Uncertainties” in this interim report. Additionally, depending on trends related to the coronavirus and future variants, the

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 5/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

COVID-19 pandemic could potentially have a material adverse impact on Genmab’s business and financial performance, including clinical trials, projected regulatory approval timelines, supply chain and revenues, and cause Genmab’s actual results to differ materially from 2022 Guidance and Key 2022 Priorities in this interim report.

Should the global outbreak of COVID-19 persist, it may have long-term impacts on the development, regulatory approval and commercialization of Genmab’s investigational medicines and on net sales of approved medicines created by Genmab and developed and marketed by Genmab or Genmab’s collaboration partners. As the pandemic continues, there may be an impact on Genmab’s business. Genmab has an established COVID-19 response team, led by the CEO, that closely monitors the evolving situation, maintains precautionary measures to help limit the impact of COVID-19 at the workplace and on our communities, and ensures business continuity. The full extent and nature of the impact of the COVID-19 pandemic and related containment measures on Genmab’s business and financial performance is uncertain as the situation continues. The factors discussed above, as well as other factors that are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab’s business and financial performance, including on the sales of Tivdak and on net sales of DARZALEX, Kesimpta, TEPEZZA and RYBREVANT by Genmab’s partners and on Genmab’s royalty and milestone revenue therefrom.

KEY 2022 PRIORITIES

Priority

Targeted Milestones

Broad and rapid development of late-stage clinical pipeline and further build US country organization

Ø
Epcoritamab1 
Expand clinical development program with multiple Phase 3 trials initiated and submission of first BLA (subject to supportive FDA feedback)

Ø
Tivdak2 
Establish Tivdak as a clear choice for 2L+ r/m Cervical Cancer patients
Broaden clinical development program including Phase 2 evaluation of combination therapy in earlier line treatment for cervical cancer and other solid tumors

Growth and development of differentiated early-stage product candidates

Ø
DuoBody®-PD-L1x4-1BB3 & DuoBody-CD40x4-1BB3 
Data from clinical expansion cohorts to progress to next steps

Ø
Expand and advance proprietary clinical product portfolio

Further scale organization aligned with growing product portfolio and brand needs

Ø
Further scale organization aligned with differentiated antibody product portfolio growth and future launches

Ø
Use solid financial base to grow and broaden antibody product and technology portfolio

1. Co-development w/ AbbVie; 2. Co-development w/ Seagen Inc. (Seagen); 3. Co-development w/ BioNTech SE (BioNTech)

PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST HALF OF 2022

At the end of the first six months of 2022, Genmab’s proprietary pipeline of investigational medicines, where we are responsible for at least 50% of development, consisted of seven antibody products in

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 6/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

clinical development. These include Genmab’s first U.S. FDA approved medicine, Tivdak, which Genmab is co-developing and co-promoting in the U.S. with Seagen. In addition to our own pipeline, there are multiple investigational medicines in development by global pharmaceutical and biotechnology companies, including four approved medicines powered by Genmab’s technology and innovations. Beyond the investigational medicines in clinical development, our pipeline also includes multiple preclinical programs. An overview of the development status of each of our investigational medicines is provided in the following sections, including updates for the second quarter of 2022. For events that occurred during the first quarter of 2022, please refer to Genmab’s Q1 2022 report. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen stock exchange and may also be found in Genmab’s filings with the U.S. Securities and Exchange Commission (SEC). Additional information is available on Genmab’s website, www.genmab.com. The information accessible through our website is not part of this report and is not incorporated by reference herein.

Genmab Proprietary Investigational Medicines1 in Development

Graphic

1Investigational medicines where Genmab has ≥50% ownership. Certain investigational medicines in co-development, partners as indicated

2See U.S. prescribing information for precise indication and safety information

3AbbVie has decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the notice period, Genmab will become solely responsible for the further development of DuoHexaBody-CD37 against low-single digit royalty payments to AbbVie, up to an agreed maximum total royalty amount, based on future potential sales of the product.

4Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 7/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Tivdak (tisotumab vedotin-tftv) – First and only U.S. FDA approved antibody-drug conjugate (ADC) for recurrent or metastatic cervical cancer

An ADC directed to tissue factor (TF), a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis
Accelerated approval granted by the U.S. FDA for Tivdak, the first and only approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
U.S. FDA approval was based on data from the innovaTV 204 (NCT03438396) Phase 2 single-arm clinical study evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent or metastatic cervical cancer
In addition to a Phase 3 study in recurrent or metastatic cervical cancer, multiple Phase 2 clinical studies in other solid tumors are ongoing
Co-developed globally and co-promoted in the U.S. in collaboration with Seagen

Tivdak is an ADC composed of Genmab’s human monoclonal antibody directed to TF and Seagen’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E to the antibody. Genmab used technology licensed from Medarex to generate the TF antibody forming part of Tivdak. Tivdak is the first and only U.S. FDA approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is being co-developed by Genmab and Seagen. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and will lead commercial operational activities in Japan. Seagen is leading commercial operational activities in the U.S. and will lead commercial operational activities in Europe and China. In these four markets there will be a 50:50 cost and profit split. In any other markets, Seagen will commercialize Tivdak and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties. The companies have joint decision-making on the worldwide development and commercialization strategy for Tivdak. The companies have a broad clinical development program for Tivdak, including a confirmatory Phase 3 study in recurrent or metastatic cervical cancer.

Please consult the U.S. Prescribing Information for Tivdak for the labeled indication and safety information, including the boxed warning.

Second Quarter 2022 Update

June: Genmab and Seagen presented multiple tisotumab vedotin abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, including interim data from the Phase 1b/2 innovaTV 205 (NCT03786081) study of tisotumab vedotin, which was presented during an oral session. The ongoing innovaTV 205 study is evaluating tisotumab vedotin as monotherapy and in combination with other agents in recurrent or metastatic cervical cancer.

Epcoritamab (DuoBody-CD3xCD20) – Potential Best-in-class Investigational Medicine

Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology platform
Multiple ongoing clinical studies across different settings and histologies, including a Phase 3 study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with more studies in planning
BLA submission to the U.S. FDA for SC epcoritamab for the treatment of patients with relapsed/refractory LBCL planned in second half of 2022
Co-developed in collaboration with AbbVie

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 8/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Epcoritamab is a proprietary bispecific antibody created using Genmab’s DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically well-validated target on malignant B-cells. Genmab used technology licensed from Medarex to generate the CD20 antibody forming part of epcoritamab. Epcoritamab is being co-developed by Genmab and AbbVie. The first Phase 3 clinical study (NCT04628494) of epcoritamab in relapsed/refractory DLBCL is ongoing. In addition, Phase 1/2 clinical studies in B-cell non-Hodgkin lymphoma (B-NHL) including chronic lymphocytic leukemia (NCT04623541) and in combination with standard of care therapies for B-NHL (NCT04663347) are ongoing. Also currently recruiting are a Phase 2 study of epcoritamab in combination with anti-neoplastic patients in adults with NHL (NCT05283720), a Phase 1 study of epcoritamab in pediatric patients with relapsed/refractory aggressive mature B-cell neoplasms (NCT05206357) and a Phase 1 study of epcoritamab either as monotherapy or in combination with standard of care therapies in adult patients with B-NHL in China (NCT05201248). The combination of epcoritamab and DuoHexaBody®-CD37 (GEN3009) is also being explored in an arm of a Phase 1/2 clinical study (NCT04358458) of DuoHexaBody-CD37 in hematologic malignancies.

Second Quarter 2022 Updates

June: Genmab announced its intent to submit a BLA to the U.S. FDA for SC epcoritamab for the treatment of patients with relapsed/refractory LBCL in the second half of 2022.
June: Genmab and AbbVie presented multiple epcoritamab abstracts at both the ASCO Annual Meeting and the 27th Annual Meeting of the European Hematology Association (EHA). Data from the first cohort of the Phase 1/2 EPCORE NHL-1 (NCT03625037) trial of epcoritamab in relapsed/refractory LBCL was presented as a late-breaking oral presentation during the Presidential Symposium at EHA.
April: Genmab and AbbVie announced topline results from the first cohort of the Phase 1/2 EPCORE NHL-1 trial of epcoritamab in relapsed/refractory LBCL. The study cohort included 157 patients with relapsed/refractory LBCL who received at least two prior lines of systemic therapy, including 38.9% who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. The topline results from this cohort demonstrated an overall response rate (ORR) of 63.1% as confirmed by an independent review committee (IRC), which exceeded the protocol prespecified threshold for efficacy. The observed median duration of response (DOR) was 12 months. The most common treatment-emergent adverse event was cytokine release syndrome (CRS) with 49.7%, including 2.5% grade 3. Based on the topline results, the companies will engage global regulatory authorities to determine next steps.

DuoBody-PD-L1x4-1BB (GEN1046) – Bispecific Next Generation Checkpoint Immunotherapy

Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology platform
Clinical studies in solid tumors ongoing, including a Phase 2 study in non-small cell lung cancer (NSCLC)
Co-developed in collaboration with BioNTech

DuoBody-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for DuoBody-PD-L1x4-1BB on a 50:50 basis. DuoBody-PD-L1x4-1BB is designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation using an inert DuoBody format. Three clinical studies in solid tumors are ongoing including a

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 9/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Phase 2 study of DuoBody-PD-L1x4-1BB as monotherapy or in combination with pembrolizumab in patients with recurrent metastatic NSCLC (NCT05117242).

DuoBody-CD40x4-1BB (GEN1042) – Potential First-in-Class Bispecific Agonistic Antibody

Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology platform
Phase 1/2 clinical study in solid tumors ongoing
Co-developed in collaboration with BioNTech

DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for DuoBody-CD40x4-1BB on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells and antigen-dependent T-cell activation, using an inert DuoBody format. A Phase 1/2 clinical study of DuoBody-CD40x4-1BB in solid tumors is ongoing (NCT04083599).

DuoHexaBody-CD37 (GEN3009) – First DuoHexaBody Program in the Clinic

Antibody-based investigational medicine created with Genmab’s DuoHexaBody technology platform
Phase 1/2 clinical study in hematologic malignancies ongoing

DuoHexaBody-CD37 (GEN3009) is a bispecific antibody that targets two non-overlapping CD37 epitopes, created using Genmab’s DuoHexaBody technology platform. The DuoHexaBody technology platform combines the dual targeting of our DuoBody technology platform with the enhanced potency of our HexaBody technology platform, creating bispecific antibodies with target-mediated enhanced hexamerization. A Phase 1/2 clinical study (NCT04358458) in hematologic malignancies, including an arm in combination with epcoritamab, is ongoing.

Second Quarter 2022 Update

June: AbbVie has decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the notice period, Genmab will become solely responsible for the further development of DuoHexaBody-CD37 against low-single digit royalty payments to AbbVie, up to an agreed maximum total royalty amount, based on future potential sales of the product.

HexaBody-CD38 (GEN3014) – HexaBody Molecule with Potential in Hematological Malignancies

Antibody-based investigational medicine created with Genmab’s HexaBody technology platform
Phase 1/2 clinical study in hematological malignancies ongoing
Developed in an exclusive worldwide license and option agreement with Janssen

HexaBody-CD38 (GEN3014) is a human CD38 monoclonal antibody-based investigational medicine created using Genmab’s HexaBody technology platform. In preclinical models of hematological malignancies HexaBody-CD38 demonstrated highly potent complement-dependent cytotoxicity and showed potent anti-tumor activity. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen to develop and commercialize HexaBody-CD38. A Phase 1/2 clinical study (NCT04824794) in hematologic malignancies is ongoing.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 10/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

DuoBody-CD3xB7H4 (GEN1047) – Most Recent Investigational Medicine in the Clinic

Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology platform
Phase 1/2 clinical study in malignant solid tumors ongoing

DuoBody-CD3xB7H4 (GEN1047) is a bispecific antibody-based investigational medicine created using Genmab’s DuoBody technology platform. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 induced T-cell mediated cytotoxicity of B7H4-positive tumor cells. DuoBody-CD3xB7H4 is being developed for the potential treatment of solid cancer indications known to express B7H4. A Phase 1/2 clinical study (NCT05180474) of DuoBody-CD3xB7H4 in malignant solid tumors is ongoing.

Products Powered by Genmab’s Technology and Innovations

In addition to Genmab’s own pipeline of investigational medicines, our innovations and proprietary technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical development programs with antibodies created by Genmab or created using Genmab’s proprietary DuoBody bispecific antibody technology platform. The programs run from Phase 1 development to approved medicines. The tables in this section include those therapies that have been approved in certain territories as well as clinical stage investigational medicines in Phase 2 development or later. Under the agreements for these products Genmab is entitled to certain potential milestones and royalties.

Approved Medicines

Graphic

*See local country prescribing information for precise indications and safety information

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 11/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

DARZALEX (daratumumab) – Redefining the Treatment of Multiple Myeloma

First-in-class human CD38 monoclonal antibody
Developed and commercialized by Janssen under an exclusive worldwide license from Genmab
Intravenous (IV) formulation approved in combination with other therapies for frontline and for relapsed/refractory multiple myeloma in territories including the U.S., Europe and Japan and as monotherapy for heavily pretreated or double-refractory multiple myeloma in territories including the U.S. and Europe
First and only SC CD38-directed antibody approved in territories including the U.S., Europe and Japan for the treatment of certain multiple myeloma indications, known as DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in the U.S., and DARZALEX SC in Europe
SC daratumumab is the first and only approved therapy for light-chain (AL) amyloidosis in the U.S., Europe and Japan
Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022

DARZALEX is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis plasma cells. Genmab used technology licensed from Medarex to generate the CD38 antibody forming part of daratumumab. Daratumumab is being developed by Janssen under an exclusive worldwide license from Genmab to develop, manufacture and commercialize daratumumab. Under the terms of the agreement, Genmab is entitled to double digit royalties between 12% and 20% with Janssen reducing its royalty payments for Genmab’s share of Janssen’s royalty payments made to Halozyme Therapeutics, Inc. (Halozyme). Daratumumab (marketed as DARZALEX for IV administration and as DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for SC administration) is approved in a large number of territories for the treatment of adult patients with certain multiple myeloma indications and is the only approved therapy in the U.S., Europe and Japan for the treatment of adult patients with AL amyloidosis.

Please consult the European Summary of Product Characteristics for DARZALEX and DARZALEX SC and the U.S. Prescribing Information for DARZALEX and DARZALEX FASPRO for the labeled indication and safety information.

Kesimpta (ofatumumab) – Approved in treatment of relapsing forms of multiple sclerosis (RMS)

Human CD20 monoclonal antibody developed and commercialized by Novartis under a license agreement with Genmab
Approved in territories including the U.S., EU and Japan for the treatment of RMS in adults
First B-cell therapy that can be self-administered by patients at home using the Sensoready® autoinjector pen

Kesimpta is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody forming part of Kesimpta. Kesimpta is approved in territories including the U.S., Europe and Japan for the treatment of certain adult patients with RMS. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once monthly after starting therapy. Kesimpta is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis. Under the terms of the agreement, Genmab is entitled to 10% royalties on net sales of Kesimpta.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 12/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Please consult the U.S. Prescribing Information and the European Summary of Product Characteristics for the labeled indication and safety information for Kesimpta.

TEPEZZA (teprotumumab-trbw) – First U.S. FDA-approved medicine for the treatment of thyroid eye disease (TED)

Developed and commercialized by Horizon Therapeutics, plc (Horizon) for the treatment of TED
First and only U.S. FDA-approved medicine for the treatment of TED
Also being explored in a clinical trial for the treatment of diffuse cutaneous systemic sclerosis (dcSSC)

Teprotumumab, approved by the U.S. FDA under the trade name TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a well-validated target. Genmab used technology licensed from Medarex to generate the IGF-1R antibody forming part of teprotumumab. The antibody was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Horizon under a sublicense from Roche. Under the terms of Genmab’s agreement with Roche, Genmab will receive mid-single digit royalties on net sales of TEPEZZA.

Please consult the U.S. Prescribing Information for the labeled indication and safety information for TEPEZZA.

RYBREVANT (amivantamab-vmjw) – First regulatory approvals for a DuoBody-based Medicine

Part of Genmab and Janssen DuoBody research and license agreement
First approved medicine created using Genmab’s proprietary DuoBody technology platform
Under the agreement with Janssen, Genmab will receive milestones and royalties on net sales of RYBREVANT

In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab’s DuoBody technology platform. The most advanced of these, Janssen’s RYBREVANT, is a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and Met, two validated cancer targets. The two antibody libraries used to produce amivantamab were both generated by Genmab. In collaboration with Janssen, the antibody pair used to create amivantamab was selected. Janssen is responsible for the development and commercialization of amivantamab.

In 2021, Janssen received approvals in the U.S., Europe and other markets for RYBREVANT for the treatment of certain adult patients with NSCLC with EGFR exon 20 insertion mutations. These are the first regulatory approvals for a therapy that was created using Genmab’s proprietary DuoBody bispecific technology platform. Under our agreement with Janssen, Genmab will receive milestones and royalties between 8% and 10% on net sales of RYBREVANT.

Please consult the U.S. Prescribing Information and the European Summary of Product Characteristics for RYBREVANT for the labeled indication and safety information.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 13/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Clinical Stage Investigational Medicines, >Phase 2 Development

Graphic

*UltiMAb transgenic mouse technology licensed from Medarex, Inc., a wholly owned subsidiary of Bristol Myers Squibb.

Preclinical Programs

Broad preclinical pipeline that includes both partnered products and in-house programs based on our proprietary technologies or antibodies
Multiple new Investigational New Drug (IND) applications expected to be submitted over coming years
Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline

Our preclinical pipeline includes immune effector function enhanced antibodies developed with our HexaBody technology platform and bispecific antibodies created with our DuoBody technology platform. We are also working with our partners to generate additional new antibody-based product concepts. A number of the preclinical programs are carried out in cooperation with our collaboration partners.

Second Quarter 2022 Update

May: IND application and first Clinical Trial Application (CTA) submitted for HexaBody-CD27 (GEN1053/BNT313). GEN1053 is being co-developed in collaboration with BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1053 on a 50:50 basis.

SIGNIFICANT RISKS AND UNCERTAINTIES

As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the industry and relate to operations, intellectual property, research and development, commercialization and financial activities. For further information about risks and uncertainties which Genmab faces, refer to the 2021 Annual Report filed with NASDAQ Copenhagen and the Form 20-F filed with the U.S. SEC, both of which were filed in February 2022. At the date of this interim report, there have been no significant changes to Genmab’s overall risk profile since the publication of these reports; however, the full extent and nature of the impact of the COVID-19 pandemic and related containment measures on our business and financial performance is uncertain. See Genmab’s Form 20-F for a detailed summary of risks related to our collaborations as well as risks related to the COVID-19 pandemic.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 14/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

FINANCIAL REVIEW

The interim report is prepared on a consolidated basis for the Genmab group. The financial statements are published in Danish Kroner (DKK).

Revenue

Genmab’s revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021. The increase of DKK 1,728 million, or 49%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our collaborations with Janssen, Roche and Novartis, respectively, partly offset by milestones achieved under our collaborations with Janssen and AbbVie in the first six months of 2021.

(DKK million)

    

6 Months Ended June 30, 2022

    

6 Months Ended June 30, 2021

Royalties

 

4,727

 

2,595

Reimbursement revenue

 

287

 

227

Milestone revenue

 

176

 

731

Collaboration revenue

91

Total revenue

 

5,281

 

3,553

Royalties

Royalty revenue amounted to DKK 4,727 million in the first six months of 2022 compared to DKK 2,595 million in the first six months of 2021. The increase of DKK 2,132 million, or 82%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our daratumumab collaboration with Janssen, teprotumumab collaboration with Roche and ofatumumab collaboration with Novartis, respectively. The table below summarizes Genmab’s royalty revenue by product.

(DKK million)

6 Months Ended June 30, 2022

6 Months Ended June 30, 2021

DARZALEX

 

4,024

 

2,360

TEPEZZA

 

390

 

162

Kesimpta

296

72

Other

17

1

Total royalties

 

4,727

 

2,595

Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022 compared to USD 2,798 million in the first six months of 2021. The increase of USD 1,044 million, or 37%, was driven by the continued strong uptake of DARZALEX. Royalty revenue on net sales of DARZALEX was DKK 4,024 million in the first six months of 2022 compared to DKK 2,360 million in the first six months of 2021, an increase of DKK 1,664 million. The percentage increase in royalties of 71% is higher than the percentage increase in the underlying net sales primarily due to the higher average exchange rate between the USD and DKK and a higher effective royalty rate for the first six months of 2022, partly offset by the increase in Genmab’s share of Janssen’s royalty payments to Halozyme in connection with SC net sales.

Net sales of TEPEZZA by Horizon were USD 981 million in the first six months of 2022 compared to USD 455 million in the first six months of 2021. TEPEZZA net sales in the first quarter of 2021 were negatively impacted by the U.S. government-mandated COVID-19 production interruption. Royalty revenue on net

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 15/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

sales of TEPEZZA was DKK 390 million in the first six months of 2022 compared to DKK 162 million in the first six months of 2021, an increase of DKK 228 million.

Net sales of Kesimpta by Novartis were USD 434 million in the first six months of 2022 compared to USD 116 million in the first six months of 2021. The increase of USD 318 million was driven by US launch momentum due to strong access and increased demand. Royalty revenue on net sales of Kesimpta was DKK 296 million in the first six months of 2022 compared to DKK 72 million in the first six months of 2021, an increase of DKK 224 million.

Janssen was granted U.S. FDA approval for RYBREVANT during the second quarter of 2021, and Genmab subsequently started recognizing royalties on net sales of RYBREVANT. Royalties were not material for the first six months of 2022 or 2021.

Royalty revenue fluctuations from period to period are due primarily to the level of product net sales, foreign currency exchange rates and more specifically to DARZALEX, Genmab’s share of Janssen’s royalty payments to Halozyme in connection with SC sales.

Reimbursement Revenue

Reimbursement revenue amounted to DKK 287 million in the first six months of 2022 compared to DKK 227 million in the first six months of 2021. The increase of DKK 60 million, or 26%, was primarily driven by higher activities under our collaboration agreement with BioNTech for DuoBody-CD40x4-1BB.

Milestone Revenue

Milestone revenue was DKK 176 million in the first six months of 2022 compared to DKK 731 million in the first six months of 2021, a decrease of DKK 555 million, or 76%, primarily driven by milestones achieved in the first six months of 2021 under our Janssen and AbbVie collaborations.

Milestone revenue may fluctuate significantly from period to period due to both the timing of achievements and the varying amount of each individual milestone under our license and collaboration agreements.

Collaboration Revenue

In September 2021, Genmab and Seagen announced U.S. FDA accelerated approval for Tivdak in previously treated recurrent or metastatic cervical cancer. Collaboration revenue was DKK 91 million for the first six months of 2022.

Refer to Financial Statement Note 2 in this interim report for further details about revenue.

Research and Development Expenses

Research and development expenses amounted to DKK 2,435 million in the first six months of 2022 compared to DKK 1,769 million in the first six months of 2021. The increase of DKK 666 million, or 38%, was driven by the continued advancement of epcoritamab under our collaboration with AbbVie, continued advancement of DuoBody-CD40x4-1BB under our collaboration with BioNTech, and the increase in new team members to support the expansion of our product pipeline.

Research and development expenses accounted for 69% of total operating expenses in the first six months of 2022 compared to 79% in the first six months of 2021.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 16/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Selling, General and Administrative Expenses

Selling, general and administrative expenses were DKK 1,085 million in the first six months of 2022 compared to DKK 465 million in the first six months of 2021. The increase of DKK 620 million, or 133%, was driven by the increase in new team members to support Tivdak post launch, continued expansion of Genmab’s commercialization capabilities in support of future launches, and investment in broader organizational infrastructure, including our technology portfolio.

Selling, general and administrative expenses accounted for 31% of total operating expenses in the first six months of 2022 compared to 21% in the first six months of 2021.

Operating Profit

Operating profit was DKK 1,761 million in the first six months of 2022 compared to DKK 1,319 million in the first six months of 2021.

Net Financial Items

Net financial items were comprised of the following:

    

6 Months Ended

    

6 Months Ended

(DKK million)

June 30, 2022

June 30, 2021

Interest and other financial income

 

87

127

Foreign exchange rate gain, net

 

1,792

573

Total financial income

 

1,879

 

700

Interest and other financial expenses

 

(10)

(6)

Loss on marketable securities, net

(315)

(134)

Loss on other investments, net

(214)

(33)

Total financial expenses

 

(539)

 

(173)

Net financial items

 

1,340

 

527

Net financial items increased by DKK 813 million, which were primarily driven by:

Increase in foreign exchange rate gain, net due to the USD strengthening against the DKK which was more favorable to our marketable securities, and cash and cash equivalents in the first six months of 2022,
Loss on marketable securities driven by increases in interest rates in the United States and Europe, and
Loss on other investments due to the decrease in fair value of Genmab’s investments in common shares of CureVac and Bolt.

Refer to Financial Statement Note 4 in this interim report for further details about the net financial items.

Corporate Tax

Corporate tax expense for the first six months of 2022 was DKK 745 million compared to DKK 444 million for the first six months of 2021. The increase in corporate tax expense is primarily the result of Genmab’s higher net result before tax. The effective tax rate in the first six months of 2022 and 2021 was 24%.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 17/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Net Profit

Net profit for the first six months of 2022 was DKK 2,356 million compared to DKK 1,402 million in the first six months of 2021. The increase was driven by the items described above.

Liquidity and Capital Resources

(DKK million)

    

June 30, 2022

    

December 31, 2021

Marketable securities

 

11,799

 

10,381

Cash and cash equivalents

 

9,816

 

8,957

Shareholders' equity

 

24,482

 

22,196

Cash Flow (DKK million)

    

6 Months Ended June 30, 2022

    

6 Months Ended June 30, 2021

Cash provided by operating activities

 

1,546

 

1,540

Cash (used in) / provided by investing activities

 

(1,243)

 

966

Cash (used in) financing activities

(278)

(460)

Exchange rate adjustments

 

834

 

171

Net cash provided by operating activities is primarily related to our operating profit, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. Cash provided by operating activities was in line with the first six months of 2021 primarily driven by an increase in operating profit of DKK 442 million offset by the timing of corporate tax payments of DKK 455 million in Denmark in the first six months of 2022 that were not required in the first six months of 2021.

Net cash (used in) / provided by investing activities primarily reflects differences between the proceeds received from the sale and maturity of our investments and amounts invested, and the cash paid for investments in tangible assets. Purchases of marketable securities exceeded sales and maturities in the first six months of 2022, whereas sales and maturities of marketable securities exceeded purchases in the first six months of 2021. For the first six months of 2021, investing activities also include the proceeds from the sale of CureVac shares of DKK 438 million. There were no sales of other investments in the first six months of 2022.

Net cash (used in) financing activities is primarily related to the purchase of treasury shares, exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net settled Restricted Stock Units (RSUs). The decrease in cash used in financing activities for the periods is primarily driven by cash payments for the purchase of treasury shares of DKK 437 million in the first six months of 2021 which were more significant than the cash payments for the purchase of treasury shares in the first six months of 2022 of DKK 211 million.

Exchange rate adjustments represent foreign currency gains or losses on Genmab’s cash and cash equivalents, primarily driven by our cash and cash equivalents holdings denominated in USD. The increase in exchange rate adjustments results from the USD strengthening against the DKK to a much greater extent in the first six months of 2022 compared to the first six months of 2021.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 18/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Genmab’s USD denominated cash and cash equivalents, and marketable securities represented 87% of Genmab’s total cash and cash equivalents, and marketable securities as of June 30, 2022 compared to 86% as of December 31, 2021.

Cash and cash equivalents included short-term marketable securities of DKK 1,006 million as of June 30, 2022 compared to DKK 296 million as of December 31, 2021. In accordance with our accounting policy, securities purchased with a maturity of less than ninety days at the date of acquisition are classified as cash and cash equivalents. Refer to Financial Statement Note 3 in this interim report for further details about our marketable securities.

Balance Sheet

As of June 30, 2022, total assets were DKK 27,476 million compared to DKK 24,627 million on December 31, 2021. As of June 30, 2022, assets were mainly comprised of marketable securities of DKK 11,799 million, cash and cash equivalents of DKK 9,816 million and current receivables of DKK 3,876 million. The current receivables consist primarily of amounts related to royalties from our collaboration agreements.

As of June 30, 2022, total liabilities were DKK 2,994 million compared to DKK 2,431 million on December 31, 2021. The increase in total liabilities of DKK 563 million, or 23%, was primarily driven by the increase in corporate tax payable due to Genmab’s net result before tax and timing of estimated tax payments, and lease liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory space.

Shareholders’ equity as of June 30, 2022 was DKK 24,482 million compared to DKK 22,196 million on December 31, 2021. The increase of DKK 2,286 million, or 10%, was driven primarily by Genmab’s net profit and share-based compensation expense related to the issuance of shares under Genmab’s warrant and RSU programs, partly offset by the purchase of treasury shares during the period. Genmab’s equity ratio was 89% as of June 30, 2022 compared to 90% as of December 31, 2021.

Team Members

As of June 30, 2022, the total number of team members was 1,445 compared to 1,029 as of June 30, 2021. The increase was primarily driven by the expansion and acceleration of our pipeline, as well as the investment in the expansion of Genmab’s commercialization capabilities, including support for Tivdak post launch and future launches, and broader organizational infrastructure.

Team Members

    

June 30, 2022

    

June 30, 2021

Research and development team members

 

1,050

793

Selling, general and administrative team members

 

395

236

Total team members

 

1,445

 

1,029

Legal Matters – Janssen Binding Arbitrations

In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for IV administration and as DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters. Genmab did not seek a review of the award, and the award is now final.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 19/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

The first matter concerned the question as to whether Janssen’s obligation to pay royalties on net sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement. As to that matter, the tribunal determined by majority opinion that Janssen’s obligation to pay royalties to Genmab on net sales of licensed product, in each applicable country, extends through the expiration or invalidation of the last-to-expire relevant Genmab-owned patent covering the product or use thereof, but not the relevant Janssen-owned patent. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s.

The second matter concerned the question as to whether Genmab is required to share in Janssen’s royalty payments to Halozyme for the Halozyme enzyme technology used in the SC formulation of daratumumab (marketed as DARZALEX FASPRO in the U.S.). The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab net sales. As to that matter, the tribunal ruled by majority opinion that Janssen is permitted to continue reducing its royalty payments to Genmab as an offset against a share of Janssen’s royalty payments made to Halozyme.

On June 9, 2022, Genmab announced the commencement of a new arbitration under the daratumumab license agreement with Janssen. This new arbitration follows from the award in the prior arbitration, where the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share in Janssen’s royalty payments to Halozyme for its technology used in the SC formulation of daratumumab. The tribunal based its ruling on the finding that DARZALEX FASPRO constitutes a new licensed product under the license agreement.

In this new arbitration, Genmab is consequently seeking an award of USD 405 million plus interest in accrued milestone payments for DARZALEX FASPRO and a declaration that it is entitled to a new 13-year royalty term from the date of DARZALEX FASPRO’s first commercial sale. See Company Announcement no. 21.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 20/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

STATEMENTS OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2022

Income Statement

2nd Quarter of

    

2nd Quarter of

2022

2021

(DKK million)

Revenue

3,162

1,972

Research and development expenses

(1,282)

(921)

Selling, general and administrative expenses

(633)

(264)

Operating expenses

(1,915)

 

(1,185)

Operating profit

1,247

 

787

Financial income

1,442

65

Financial expenses

(200)

(430)

Net profit before tax

2,489

 

422

Corporate tax

(598)

(116)

Net profit

1,891

 

306

Basic net profit per share

28.87

4.68

Diluted net profit per share

28.66

4.64

Statement of Comprehensive Income

  

 

  

Net profit

1,891

 

306

Other comprehensive income:

  

 

  

Amounts which will be re-classified to the income statement:

  

 

  

Adjustment of foreign currency fluctuations on subsidiaries

13

(13)

Total comprehensive income

1,904

 

293

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 21/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

STATEMENTS OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2022

Income Statement

    

6 Months Ended

    

6 Months Ended

Note

 

June 30, 2022

June 30, 2021

(DKK million)

 

Revenue

2

 

5,281

3,553

Research and development expenses

 

(2,435)

(1,769)

Selling, general and administrative expenses

 

(1,085)

(465)

Operating expenses

 

(3,520)

(2,234)

Operating profit

 

1,761

1,319

Financial income

4

 

1,879

700

Financial expenses

4

(539)

(173)

Net profit before tax

 

3,101

1,846

Corporate tax

 

(745)

(444)

Net profit

 

2,356

1,402

Basic net profit per share

 

35.97

21.44

Diluted net profit per share

 

35.71

21.25

Statement of Comprehensive Income

 

  

  

Net profit

 

2,356

1,402

Other comprehensive income:

  

 

Amounts which will be re-classified to the income statement:

  

 

Adjustment of foreign currency fluctuations on subsidiaries

29

28

Total comprehensive income

2,385

1,430

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 22/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

BALANCE SHEETS

    

    

June 30, 

    

December 31, 

Note

2022

2021

(DKK million)

ASSETS

 

  

 

  

 

  

Intangible assets

 

  

 

216

 

254

Property and equipment

 

  

 

684

 

621

Right-of-use assets

 

7

 

554

 

354

Receivables

 

  

 

66

 

27

Deferred tax assets

 

  

 

264

 

264

Other investments

3

201

371

Total non-current assets

 

  

 

1,985

 

1,891

Corporate tax receivable

31

Receivables

 

  

 

3,876

 

3,367

Marketable securities

 

3

 

11,799

 

10,381

Cash and cash equivalents

 

  

 

9,816

 

8,957

Total current assets

 

  

 

25,491

 

22,736

Total assets

 

  

 

27,476

 

24,627

SHAREHOLDERS’ EQUITY AND LIABILITIES

 

  

 

  

 

  

Share capital

 

  

 

66

 

66

Share premium

 

  

 

12,063

 

12,029

Other reserves

 

  

 

110

 

81

Retained earnings

 

  

 

12,243

 

10,020

Total shareholders' equity

 

  

 

24,482

 

22,196

Provisions

 

  

 

7

 

13

Lease liabilities

 

7

 

554

 

363

Deferred revenue

487

487

Other payables

 

  

 

2

 

Total non-current liabilities

 

  

 

1,050

 

863

Provisions

 

  

 

6

 

Corporate tax payable

257

Lease liabilities

 

7

 

80

 

62

Deferred revenue

26

26

Other payables

 

  

 

1,575

 

1,480

Total current liabilities

 

  

 

1,944

 

1,568

Total liabilities

 

  

 

2,994

 

2,431

Total shareholders' equity and liabilities

 

  

 

27,476

 

24,627

Share-based instruments

 

5

 

  

 

  

Related parties

 

6

 

  

 

  

Subsequent events to the balance sheet date

 

8

 

  

 

  

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 23/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

STATEMENTS OF CASH FLOWS

6 Months Ended

    

6 Months Ended

    

Note

    

June 30, 2022

    

June 30, 2021

(DKK million)

Net profit before tax

3,101

1,846

Reversal of financial items, net

(1,340)

(527)

Adjustments for non-cash transactions

347

227

Changes in operating assets and liabilities

(179)

(105)

Cash flows from operating activities before financial items

1,929

1,441

Interest received

80

107

Interest elements of lease payments

7

(7)

(6)

Interest paid

(1)

Corporate taxes paid

(455)

(2)

Net cash provided by operating activities

1,546

1,540

Investment in tangible assets

(125)

(107)

Marketable securities bought

(4,061)

(7,410)

Marketable securities sold

2,965

8,137

Other investments bought

(22)

(92)

Other investments sold

438

Net cash (used in) / provided by investing activities

(1,243)

966

Warrants exercised

34

46

Principal elements of lease payments

(30)

(29)

Purchase of treasury shares

(211)

(437)

Payment of withholding taxes on behalf of employees on net settled RSUs

(71)

(40)

Net cash (used in) financing activities

(278)

(460)

Change in cash and cash equivalents

25

2,046

Cash and cash equivalents at the beginning of the period

8,957

7,260

Exchange rate adjustments

834

171

Cash and cash equivalents at the end of the period

9,816

9,477

Cash and cash equivalents include:

Bank deposits

8,810

6,908

Short-term marketable securities

1,006

2,569

Cash and cash equivalents at the end of the period

9,816

9,477

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 24/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

STATEMENTS OF CHANGES IN EQUITY

    

Share

    

Share

    

Translation

    

Retained

    

Shareholders'

capital

premium

reserves

earnings

equity

(DKK million)

 

Balance at December 31, 2020

 

66

 

11,894

 

54

 

7,107

 

19,121

Net profit

 

1,402

 

1,402

Other comprehensive income

 

28

 

28

Total comprehensive income

 

 

 

28

 

1,402

 

1,430

Transactions with owners:

 

  

 

  

 

  

 

  

 

  

Exercise of warrants

 

46

 

46

Purchase of treasury shares

 

(447)

 

(447)

Share-based compensation expenses

142

142

Net settlement of RSUs

 

(40)

 

(40)

Balance at June 30, 2021

 

66

11,940

82

8,164

20,252

Balance at December 31, 2021

 

66

 

12,029

 

81

 

10,020

 

22,196

Net profit

 

2,356

 

2,356

Other comprehensive income

 

29

 

29

Total comprehensive income

 

 

 

29

 

2,356

 

2,385

Transactions with owners:

 

  

 

  

 

  

 

  

 

  

Exercise of warrants

 

34

 

34

Purchase of treasury shares

 

(270)

 

(270)

Share-based compensation expenses

 

208

 

208

Net settlement of RSUs

 

(71)

 

(71)

Balance at June 30, 2022

 

66

12,063

110

12,243

24,482

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 25/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

NOTES TO THE FINANCIAL STATEMENTS

Note 1 – Basis of Presentation

Accounting Policies

These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab’s external auditors.

The interim report has been prepared using the same accounting policies as outlined in Section 1 – Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report.

Management Judgements and Estimates under IFRS

In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group’s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.

Information about Geographical Areas

Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 41

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 26/35

1560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

Graphic

Interim Report for the First Half of 2022

Note 2 – Revenue

The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by product, under Genmab’s agreements.

    

6 Months Ended

    

6 Months Ended

June 30, 2022

June 30, 2021

(DKK million)

Revenue by type:

 

 

  

Royalties

 

4,727

 

2,595

Reimbursement revenue

 

287

 

227

Milestone revenue